

# SUSPECTED ADVERSE DRUG REACTION REPORTING FORM (FOR DRUGS USED IN PROPHYLAXIS/TREATMENT OF COVID-19)

For **VOLUNTARY** reporting of ADRs by Healthcare Professionals

**INDIAN PHARMACOPOEIA COMMISSION** (National Coordination Centre-Pharmacovigilance Programme of India) Ministry of Health & Family Welfare, Government of India, Sector-23, Raj Nagar, Ghaziabad-201002

PvPI Helpline (Toll Free): 1800-180-3024 (9:00 AM to 5:30 PM, Monday-Friday)

A. PATIENT/SUBJECT	T INFORMATION	ON								
Patient/Subject Cate			Reg. No./IPD No./OPD No./CR No. :							
a. Lab confirmed COVI			AMC Report No. :							
b. Asymptomatic Healt	hcare Worker in	volved in the	Worldwide Unique No. : To be generated by PvPI							
care of suspected or			9. Relevant tests/laboratory data with dates							
c. Asymptomatic house confirmed cases	hold contacts o	f laboratory		Test for COVID-19 :						
d. Others (Please speci	fv)			RT PCR Test □ Rapid Antibody Test □						
1. Patient/Subject	2. Age/Date	3. Weight (in Kg	)	1	□ Not done □					
initials	of Birth	J. Helghe (iii Ng	,	ga						
4. Gender :	5. If female	6. Lactating		10. Any other tests performed :						
Male $\square$ Female $\square$	pregnant			1. Chest X-Ray	Yes □ No □					
Transgender $\square$	Yes □ No □	Yes □ No □		2. ECG Findings, if any	Yes □ No □					
B. SUSPECTED ADVE	RSE REACTIO	N		3. Biochemical Examination such as Serum Electrolytes (Na, K, Mg, Ca etc.)	Yes □ No □					
S.No. Reaction	Start	End Outcome*		4. Ophthalmology Exam findings, if any	Yes □ No □					
	Date	Date		5. Radiological examination	Yes □ No □					
				6. Other Relevant information, if any						
				11. Recent Travel Information :						
				Recent History of International Travel:	Yes □ No □					
* Outcome may be indi	• •	_		Country Visited :						
		Recovered with sequelae	е	Date of Return to India : Inter-state travel/domestic travel						
(d) Recovering (e) Fa	tal <b>(f)</b>	Unknown		Intel state travely domestic travel						
7. Describe Event(s)		with treatment deta	ils,	12. Relevant medical/medication his	tory :					
if any in chronolo	gical order			Allergy/Hypersensitivity Reaction						
				Chronic Alcoholism						
				Smoking						
				Obesity						
				Renal Dysfunction Hepatic Dysfunction						
				Diabetes						
				Epilepsy/Seizures						
				Bronchial Asthma						
				Cardiovascular Disease						
				Chronic Lung Disease						
				Immunodeficiency Disorder Immunosuppressant Drug						
				Anaemia						
				Neurological disorder						
				G-6-PD Deficiency						
				Dermatological findings, if any						
				Others						
8. Seriousness of the	e reaction :			13. Drug Interaction : Mention name of	f any interacting					
No $\square$ if Yes $\square$ (p	ease tick appro	priate box)		(with Suspected Drug) drug taken :						
Death (dd/mm/yyy)										
Life threatening										
Hospitalization/Prol	ongation of hosi	oitalization								
Other Medically imp										

#### SUSPECTED MEDICINE(S) **Drug Name** Manufacturer/ Batch Exp. Dosage Dose Route Frequency Therapy Dates Indication Casualty Date No. (Brand/Generic) MAH# used Once a day, **Assessment** No./Lot Form of Date Date (if known) No. (if known) Admn. Twice a day (Prefer WHOstarted stopped UMC Scale) etc.) i. ii. iii. iv.

S.No.	Drug Name	Reaction abated on (please tick)					Reaction if reappeared after drug reintroduction			
		Drug withdrawal	Dose reduction	Without modification of dose	Any other	Yes	No	Effect unknown	Dose (if reintroduced)	
i.										
ii.										
iii.										

14. Concomitant medication including drug used for co-morbidities, and complementary medicines with therapy dates (Exclude those used to treat reaction)

l	S.No.	Name (Brand/Generic)	Dose used	Route used	Frequency (Once a	Therapy Dates		Indication
					day, twice a day etc.	Date started	Date stopped	
	i.							
	ii.							
	iii.							
	iv.							

		-	-	^		-	-	ъ.	-	-	
D.	1.74		-	u	1.73			ĸ	 -	•	_

<b>15.</b> Name of	the Healthcare Professional with Addres	ss:
Pin :	E-mail :	Tel. No. (with STD code) :
Occupation:		Signature :
<b>16</b> Data of t	h:	

# **16.** Date of this report (dd/mm/yyy) :

#### Sign. and Name of Receiver -

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction. Submission of an ADR report does not have any legal implication on the reporter.

\* Use separate page for more information, #MAH-Marketing Authorization Holder

### **ADVICE ABOUT REPORTING**

## A. What to report?

#### All adverse events should be reported

Report every serious adverse drug reactions. A reaction is serious when the patient outcome is :

- Death
- Life-threatening
- Hospitalization (initial or prolonged)

Report all non-serious, known or unknown, frequent or rare adverse drug reactions.

# B. Who can report?

All healthcare professionals (Clinicians, Dentists, Pharmacists and Nurse etc.) can report adverse drug reactions

#### C. Where to report?

Duty filled in Suspected Adverse Drug Reaction Reporting Form can be sent to the nearest Adverse Drug Reaction Monitoring Centre (AMC) or directly to the National Coordination Centre (NCC) for PvPI.

Call on Helpline (Toll Free) 1800 180 3024 to report ADRs or directly mail this filled form to <a href="mailto:pvpi.ipc@gov.in">pvpi.ipc@gov.in</a>

A list of nationwide AMCs is available at : http://www.ipc.gov.in, http://www.ipc.gov.in/PvPI/pv\_home.html

#### D. What happens to the submitted information?

Information provided in this form is handled in strict confidence. The causality assessment is carried out at AMCs by using WHO-UMC scale. The analyzed forms are forwarded to the NCC-PvPI through ADR database. Finally the data is analyzed and forwarded to the Global Pharmacovigilance Database managed by WHO Uppsala Monitoring Centre in Sweden.

The reports are periodically reviewed by the NCC-PvPI. The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines.

The Signal Review Panel of PvPI reviews the data and suggests any interventions that may be required.

#### E. Mandatory fields for suspected ADR Reporting Form

Patient initials, age at onset of reaction, reaction term(s), date of onset of reaction, suspected medication(s) & reporter information.

#### For Adverse Drug Reaction Reporting Tools

- E-mail: <a href="mailto:pvpi.ipc@gov.in">pvpi.ipc@gov.in</a>
- > **PvPI Helpline (Toll Free): 1800 180 3024** (9:00 AM to 5:30 PM, Monday-Friday)
- > ADR Mobile App: "ADRPvPI"